Strontium
Bone-seeking mineral with real fracture data — but cardiac safety flags.
What is Strontium?
Strontium is a mineral used for reduce vertebral fracture risk. NutriDex grades the human evidence as Moderate. Strontium is a calcium-like mineral that deposits in bone and slows resorption. The prescription salt strontium ranelate is the best-studied form: in the 3-year SOTI trial (n=1,649) it reduced new vertebral fractures by 41%, and in TROPOS it cut non-vertebral fractures by 16% and hip fractures by 36% in high-risk women. Network meta-analysis ranks it first for total-hip bone density. However, DEXA overstates real gains because strontium's heavy atom inflates the reading. Crucially, trials showed more heart attacks (about 1.7% vs 1.1%) plus a venous-clotting and severe-skin-reaction (DRESS) signal, so European regulators restricted it to severe osteoporosis and it has since been largely withdrawn. Over-the-counter strontium citrate, marketed as a 'natural' alternative, has minimal direct fracture evidence and likely carries the same risks.
Purported Benefits
Evidence by outcome
The same supplement can be well-proven for one use and unproven for another — here is the human evidence graded outcome by outcome.
| Outcome | Evidence | Effect | Studies |
|---|---|---|---|
| Reduce vertebral fracture riskSOTI RCT cut new vertebral fractures 41% over 3y; sustained at 5y. Applies to prescription ranelate, not OTC citrate. | Strong | ↑ benefit · large | 3 |
| Reduce non-vertebral & hip fracture riskTROPOS RCT cut non-vertebral fractures 16% and hip 36%, but only in high-risk women aged >=74. | Moderate | ↑ benefit · moderate | 1 |
| Raise bone mineral densityNetwork meta-analysis ranked it first for total-hip BMD, but DEXA overstates real gains via the heavy strontium atom. | Moderate | ↑ benefit | 1 |
| Cardiovascular harm (myocardial infarction)Pooled RCT data showed more MI (1.7% vs 1.1%); prompted EMA restriction and near-withdrawal. | Moderate | ⚠ risk · small | 1 |
| Venous thromboembolism riskPrescription-event monitoring of 10,782 users found VTE 6.24/1,000 patient-years, matching the trial clotting signal. | Moderate | ⚠ risk · small | 1 |